Analysis of IL-6-mediated growth control of myeloma cells using a gp130 chimeric receptor approach

J. D. French, R. C. Tschumper, Diane F Jelinek

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Interleukin 6 (IL-6) has been shown to be a key growth factor for myeloma cells. To study IL-6 signal transduction in multiple myeloma (MM), we employed chimeric receptors composed of the epidermal growth factor receptor (EGFR) extracellular domain, gp130 transmembrane domain, and full-length or truncated gp130 cytoplasmic domains lacking regions previously shown to be necessary for MAPK, STAT1, and STAT3 activation. The IL-6-dependent KAS-6/1 MM cell line was transfected with various chimeric receptor constructs and assayed for EGF responsiveness. EGF stimulation surprisingly stimulated DNA synthesis in all transfectants, regardless of receptor length. When cell proliferation was assayed instead, only transfectants capable of inducing high levels of STAT3 activation proliferated in response to EGF. Additional studies revealed that EGF stimulation resulted in tyrosine phosphorylation of endogenous gp130 in cells expressing the chimeric receptor. Replacing the gp130 transmembrane region with the EGFR transmembrane domain diminished but did not disrupt this interaction. This receptor interaction was also observed in the IL-6-dependent MM cell line ANBL-6. In summary, although our results suggest that STAT activation is crucial in gp130-mediated proliferation of myeloma cells, these results must be interpreted with caution given our demonstration of the interaction between chimeric and endogenous receptors in myeloma cells. Importantly, this interaction has not been noted in studies utilizing the same gp130 chimeric receptor system in non-MM cells.

Original languageEnglish (US)
Pages (from-to)1189-1196
Number of pages8
JournalLeukemia
Volume16
Issue number6
DOIs
StatePublished - 2002

Fingerprint

Epidermal Growth Factor
Interleukin-6
Multiple Myeloma
Growth
Epidermal Growth Factor Receptor
Cell Proliferation
Cell Line
Tyrosine
Signal Transduction
Intercellular Signaling Peptides and Proteins
Phosphorylation
DNA

Keywords

  • Chimeric receptor
  • gp130
  • Interleukin-6
  • Lateral signal transduction
  • Multiple myeloma

ASJC Scopus subject areas

  • Hematology
  • Cancer Research
  • Anesthesiology and Pain Medicine

Cite this

Analysis of IL-6-mediated growth control of myeloma cells using a gp130 chimeric receptor approach. / French, J. D.; Tschumper, R. C.; Jelinek, Diane F.

In: Leukemia, Vol. 16, No. 6, 2002, p. 1189-1196.

Research output: Contribution to journalArticle

@article{0ae73ce4d0ae4c498ea605913e241cd6,
title = "Analysis of IL-6-mediated growth control of myeloma cells using a gp130 chimeric receptor approach",
abstract = "Interleukin 6 (IL-6) has been shown to be a key growth factor for myeloma cells. To study IL-6 signal transduction in multiple myeloma (MM), we employed chimeric receptors composed of the epidermal growth factor receptor (EGFR) extracellular domain, gp130 transmembrane domain, and full-length or truncated gp130 cytoplasmic domains lacking regions previously shown to be necessary for MAPK, STAT1, and STAT3 activation. The IL-6-dependent KAS-6/1 MM cell line was transfected with various chimeric receptor constructs and assayed for EGF responsiveness. EGF stimulation surprisingly stimulated DNA synthesis in all transfectants, regardless of receptor length. When cell proliferation was assayed instead, only transfectants capable of inducing high levels of STAT3 activation proliferated in response to EGF. Additional studies revealed that EGF stimulation resulted in tyrosine phosphorylation of endogenous gp130 in cells expressing the chimeric receptor. Replacing the gp130 transmembrane region with the EGFR transmembrane domain diminished but did not disrupt this interaction. This receptor interaction was also observed in the IL-6-dependent MM cell line ANBL-6. In summary, although our results suggest that STAT activation is crucial in gp130-mediated proliferation of myeloma cells, these results must be interpreted with caution given our demonstration of the interaction between chimeric and endogenous receptors in myeloma cells. Importantly, this interaction has not been noted in studies utilizing the same gp130 chimeric receptor system in non-MM cells.",
keywords = "Chimeric receptor, gp130, Interleukin-6, Lateral signal transduction, Multiple myeloma",
author = "French, {J. D.} and Tschumper, {R. C.} and Jelinek, {Diane F}",
year = "2002",
doi = "10.1038/sj.leu.2402411",
language = "English (US)",
volume = "16",
pages = "1189--1196",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - Analysis of IL-6-mediated growth control of myeloma cells using a gp130 chimeric receptor approach

AU - French, J. D.

AU - Tschumper, R. C.

AU - Jelinek, Diane F

PY - 2002

Y1 - 2002

N2 - Interleukin 6 (IL-6) has been shown to be a key growth factor for myeloma cells. To study IL-6 signal transduction in multiple myeloma (MM), we employed chimeric receptors composed of the epidermal growth factor receptor (EGFR) extracellular domain, gp130 transmembrane domain, and full-length or truncated gp130 cytoplasmic domains lacking regions previously shown to be necessary for MAPK, STAT1, and STAT3 activation. The IL-6-dependent KAS-6/1 MM cell line was transfected with various chimeric receptor constructs and assayed for EGF responsiveness. EGF stimulation surprisingly stimulated DNA synthesis in all transfectants, regardless of receptor length. When cell proliferation was assayed instead, only transfectants capable of inducing high levels of STAT3 activation proliferated in response to EGF. Additional studies revealed that EGF stimulation resulted in tyrosine phosphorylation of endogenous gp130 in cells expressing the chimeric receptor. Replacing the gp130 transmembrane region with the EGFR transmembrane domain diminished but did not disrupt this interaction. This receptor interaction was also observed in the IL-6-dependent MM cell line ANBL-6. In summary, although our results suggest that STAT activation is crucial in gp130-mediated proliferation of myeloma cells, these results must be interpreted with caution given our demonstration of the interaction between chimeric and endogenous receptors in myeloma cells. Importantly, this interaction has not been noted in studies utilizing the same gp130 chimeric receptor system in non-MM cells.

AB - Interleukin 6 (IL-6) has been shown to be a key growth factor for myeloma cells. To study IL-6 signal transduction in multiple myeloma (MM), we employed chimeric receptors composed of the epidermal growth factor receptor (EGFR) extracellular domain, gp130 transmembrane domain, and full-length or truncated gp130 cytoplasmic domains lacking regions previously shown to be necessary for MAPK, STAT1, and STAT3 activation. The IL-6-dependent KAS-6/1 MM cell line was transfected with various chimeric receptor constructs and assayed for EGF responsiveness. EGF stimulation surprisingly stimulated DNA synthesis in all transfectants, regardless of receptor length. When cell proliferation was assayed instead, only transfectants capable of inducing high levels of STAT3 activation proliferated in response to EGF. Additional studies revealed that EGF stimulation resulted in tyrosine phosphorylation of endogenous gp130 in cells expressing the chimeric receptor. Replacing the gp130 transmembrane region with the EGFR transmembrane domain diminished but did not disrupt this interaction. This receptor interaction was also observed in the IL-6-dependent MM cell line ANBL-6. In summary, although our results suggest that STAT activation is crucial in gp130-mediated proliferation of myeloma cells, these results must be interpreted with caution given our demonstration of the interaction between chimeric and endogenous receptors in myeloma cells. Importantly, this interaction has not been noted in studies utilizing the same gp130 chimeric receptor system in non-MM cells.

KW - Chimeric receptor

KW - gp130

KW - Interleukin-6

KW - Lateral signal transduction

KW - Multiple myeloma

UR - http://www.scopus.com/inward/record.url?scp=85014217410&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85014217410&partnerID=8YFLogxK

U2 - 10.1038/sj.leu.2402411

DO - 10.1038/sj.leu.2402411

M3 - Article

VL - 16

SP - 1189

EP - 1196

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 6

ER -